Lighthouse Pharma

Lighthouse Pharmaceuticals is a clinical-stage private biopharmaceutical company that has pioneered precision medicine approaches to address unmet medical needs, based on expertise in small-molecule protease inhibition. Lighthouse's lead program, LHP588, has entered Phase 2 clinical studies, targeting a specific infectious pathogen, Porphyromonas gingivalis, which is associated with chronic degenerative and inflammatory conditions including dementia, periodontal disease, atherosclerosis, and orodigestive cancers.